Prolyl endopeptidase activity is correlated with colorectal cancer prognosis

International Journal of Medical Sciences

Volumn 11, Issue 2, 2014, Pages 199-208

  Larrinaga, Gorka ^a,d   Perez, Itxaro ^a,d   Blanco, Lorena ^a,d   Sanz, Begoña ^a,d   Errarte, Peio ^a,d   Beitia, Maider ^a,d   Etxezarraga, María C ^b,d   Loizate, Alberto ^b,d   Gil, Javier ^a,d   Irazusta, Jon ^a,d   López, José I ^c,d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

Colorectal cancer; Pep; Prognosis; Prolyl endopeptidase; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; PROLYL ENDOPEPTIDASE;

AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLON RESECTION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENZYME ACTIVITY; FEMALE; FLUOROMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

COLORECTAL CANCER; PEP; PROGNOSIS; PROLYL ENDOPEPTIDASE; SURVIVAL.;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84892184037     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.7178     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013; 63(1):11-30.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46:765-81.
3. Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012; 27:613-23.
4. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50: 113-30.
5. Kim EC, Lance P. Colorectal polyps and their relationship to cancer. Gastroenterol Clin North Am. 1997; 26:1-17.
6. Carl-McGrath S, Lendeckel U, Ebert M et al. Ectopeptidases in tumor biology: A review. Histol Histopathol. 2006; 21:1339-53.
7. Cordero OJ, Ayude D, Nogueira M, et al. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 2000; 80:1139-46.
8. Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. 2002; 122:376-86.
9. Ikeda N, Nakajima Y, Tokuhara T, et al. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 2003; 9:1503-08.
10. Murakami H, Yokoyama A, Kondo K, et al. Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res. 2005; 11:8674-79.
11. Tokuhara T, Hattori N, Ishida H, et al. Clinical significance os aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 2006; 12:3971-78.
12. Larrinaga G, Blanco L, Sanz B, et al. The impact of peptidase activity in clear cell renal cell carcinoma survival. Am J Physiol Renal Physiol. 2012; 303:F1584-91.
13. Szeltner Z, Polgár L. Structure, Function and Biological Relevance of Prolyl Oligopeptidase. Curr Protein Pept Sci. 2008; 9:96-107.
14. Goossens F, De Meester I, Vanhoof G, et al. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem. 1996; 34:17-22.
15. Irazusta J, Larrinaga G, González-Maeso J, et al. Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem Int. 2002; 40:337-45.
16. Tenorio-Laranga J, Venäläinen JI, Männistö PT, et al. Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J. 2008; 275:4415-27.
17. García-Hornsman JA, Männistö PT, Venäläinen JI. On the role of prolyl oligopeptidase in health and disease. Neuropeptides. 2007; 41:1-24.
18. Myöhänen TT, Venäläinen JI, García-Hornsman JA, et al. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol. 2008; 130:993-1003.
19. Myöhänen TT, Pyykkö E, Männistö PT, et al. Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal s. J Histochem Cytochem. 2012;60:706-15.
20. Agirregoitia N, Casis L, Gil J, et al. Ontogeny of prolyl endopeptidase and pyroglutamyl peptidase I in rat tissues. Regul Pept. 2007; 139:52-8.
21. Moreno-Baylach MJ, Felipo V, Männisto PT, et al. Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience. 2008; 156:580-5.
22. Sedo A, Krepela E, Kasafírek E. Dipeptidil peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumors and lung parenchyma. J Cancer Res Clin Oncol. 1991; 117:249-53.
23. Liu JL, Kusinski M, Ilic V, et al. Overexpression of the angiogenin tetrapeptide AcSDKP in human malignant s. Anticancer Res. 2008;28:2813-18.
24. Larrinaga G, Perez I, Blanco L, et al. Increased prolyl endopeptidase activity in human neoplasia. Regul Pept. 2010; 163:102-106.
25. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th Edition. New York: Springer. 2010.
26. Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009; 133:1539-51.
27. Olivo RA, Pereira Teixeira PT, Silveira PF. Representative aminopeptidases and prolyl endopeptidase from murine macrophages: comparative activity levels in resident and elicited cells. Biochem Pharmacol. 2005; 69:1441-50.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54
29. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002; 89:845-60.
30. Unsal Kilic D, Uner A, Akyurek N, et al. Matrix metalloproteinase-9 expression correlated with response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007; 67:196-203.
31. Nishioka M, Shimada M, Kurita N, et al. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. Cancer Genomics Proteomics. 2011; 8:87-92.
32. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009; 58:1723-47.
33. De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, et al. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer. 2010;10:333.
34. Bünger S, Haug U, Kelly M, et al. A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. BMC Cancer. 2012; 12:393.
35. Javidroozi M, Zucker S, Chen WT. Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis Markers. 2012; 32:309-20.
36. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intraal fluid. Clin Cancer Res. 2002; 8:3747-54.
37. Liu JM, Bignon J, Ilic V, et al. Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development. Leuk Lymphoma. 2006; 47:1915-20.
38. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008; 29:1675-84.
39. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008; 180: 5662-9.
40. Moreno-Baylach MJ, Puttonen KA, Tenorio-Laranga J, et al. Prolyl endopeptidase is involved in cellular signalling in human neuroblastoma SH-SY5Y cells. Neurosignals. 2011; 19: 97-109.
41. Myöhänen TT, Tenorio-Laranga J, Jokinen B, et al. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br J Pharmacol. 2011; 163: 1666-78.
42. Mina-Osorio P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med. 2008; 14:361-71.
43. Ino K, Shibata K, Kajiyama H, et al. Regulatory role of membrane-bound peptidases in the progression of gynecologic malignancies. Biol Chem. 2004; 385:683-90.
44. Kikkawa F, Kajiyama H, Shibata K, et al. Dipeptidyl peptidase IV in progression. Biochim Biophys Acta. 2005;1751:45-51.
45. Varona A, Blanco L, Perez I, et al. Expression and activity profiles of DPPIV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are -type dependent. BMC Cancer. 2010; 10:193.
46. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012; 11:257-66.
47. Wickström M, Larsson R, Nygren P, et al. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011; 102:501-08.
48. Brennen WN, Rosen DM, Wang H, et al. Targeting carcinoma-associated fibroblasts within the stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012; 104:1320-34.
49. Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007; 13:1736-41.